Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICE 1204
- Development stage
- Preclinical
- Lead developer
- iCeutica
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
ICE 1204 is a preclinical-stage small molecule therapeutic being developed by iCeutica for the treatment of respiratory and allergic diseases, including asthma and chronic obstructive pulmonary disease (COPD). The drug is designed for inhaled administration. iCeutica utilizes its proprietary SoluMatrix Fine Particle Technology to produce sub-micron drug particles, which aims to improve the solubility and bioavailability of the active pharmaceutical ingredient. As of the latest pipeline updates, the specific biological target and the identity of the small molecule have not been publicly disclosed.
02
Targets
AChR (Acetylcholine receptor)
Beyond the preview
Go deeper on ICE 1204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICE 1204.